159 related articles for article (PubMed ID: 22406446)
1. Amyloid-β metabolite sensing: biochemical linking of glycation modification and misfolding.
Fawver JN; Schall HE; Petrofes Chapa RD; Zhu X; Murray IV
J Alzheimers Dis; 2012; 30(1):63-73. PubMed ID: 22406446
[TBL] [Abstract][Full Text] [Related]
2. Lipid oxidation and modification of amyloid-β (Aβ) in vitro and in vivo.
Ellis G; Fang E; Maheshwari M; Roltsch E; Holcomb L; Zimmer D; Martinez D; Murray IV
J Alzheimers Dis; 2010; 22(2):593-607. PubMed ID: 20847409
[TBL] [Abstract][Full Text] [Related]
3. Adenosine triphosphate (ATP) reduces amyloid-β protein misfolding in vitro.
Coskuner O; Murray IV
J Alzheimers Dis; 2014; 41(2):561-74. PubMed ID: 24625803
[TBL] [Abstract][Full Text] [Related]
4. The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation.
Siegel SJ; Bieschke J; Powers ET; Kelly JW
Biochemistry; 2007 Feb; 46(6):1503-10. PubMed ID: 17279615
[TBL] [Abstract][Full Text] [Related]
5. Glycation of Lys-16 and Arg-5 in amyloid-β and the presence of Cu
Fica-Contreras SM; Shuster SO; Durfee ND; Bowe GJK; Henning NJ; Hill SA; Vrla GD; Stillman DR; Suralik KM; Sandwick RK; Choi S
J Biol Inorg Chem; 2017 Dec; 22(8):1211-1222. PubMed ID: 29038915
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Impact of Glyoxal Glycation on β-Amyloid Peptide (Aβ) Aggregation in Alzheimer's Disease.
Hu KW; Fan HF; Lin HC; Huang JW; Chen YC; Shen CL; Shih YH; Tu LH
J Phys Chem B; 2021 Jun; 125(21):5559-5571. PubMed ID: 34019761
[TBL] [Abstract][Full Text] [Related]
7. Hydralazine modifies Aβ fibril formation and prevents modification by lipids in vitro.
Maheshwari M; Roberts JK; Desutter B; Duong KT; Tingling J; Fawver JN; Schall HE; Kahle M; Murray IV
Biochemistry; 2010 Dec; 49(49):10371-80. PubMed ID: 21058733
[TBL] [Abstract][Full Text] [Related]
8. Posttranslational nitro-glycative modifications of albumin in Alzheimer's disease: implications in cytotoxicity and amyloid-β peptide aggregation.
Ramos-Fernández E; Tajes M; Palomer E; Ill-Raga G; Bosch-Morató M; Guivernau B; Román-Dégano I; Eraso-Pichot A; Alcolea D; Fortea J; Nuñez L; Paez A; Alameda F; Fernández-Busquets X; Lleó A; Elosúa R; Boada M; Valverde MA; Muñoz FJ
J Alzheimers Dis; 2014; 40(3):643-57. PubMed ID: 24503620
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
10. Glycation affects fibril formation of Aβ peptides.
Emendato A; Milordini G; Zacco E; Sicorello A; Dal Piaz F; Guerrini R; Thorogate R; Picone D; Pastore A
J Biol Chem; 2018 Aug; 293(34):13100-13111. PubMed ID: 29959224
[TBL] [Abstract][Full Text] [Related]
11. Brain amyloid-beta fragment signatures in pathological ageing and Alzheimer's disease by hybrid immunoprecipitation mass spectrometry.
Portelius E; Lashley T; Westerlund A; Persson R; Fox NC; Blennow K; Revesz T; Zetterberg H
Neurodegener Dis; 2015; 15(1):50-7. PubMed ID: 25591542
[TBL] [Abstract][Full Text] [Related]
12. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
Güntert A; Döbeli H; Bohrmann B
Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
[TBL] [Abstract][Full Text] [Related]
13. Cross-talk between Aβ and endothelial SSAO/VAP-1 accelerates vascular damage and Aβ aggregation related to CAA-AD.
Solé M; Miñano-Molina AJ; Unzeta M
Neurobiol Aging; 2015 Feb; 36(2):762-75. PubMed ID: 25457560
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.
Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z
Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol decreases the insoluble Aβ1-42 level in hippocampus and protects the integrity of the blood-brain barrier in AD rats.
Zhao HF; Li N; Wang Q; Cheng XJ; Li XM; Liu TT
Neuroscience; 2015 Dec; 310():641-9. PubMed ID: 26454022
[TBL] [Abstract][Full Text] [Related]
16. Glycation, Glycolysis, and Neurodegenerative Diseases: Is There Any Connection?
Muronetz VI; Melnikova AK; Seferbekova ZN; Barinova KV; Schmalhausen EV
Biochemistry (Mosc); 2017 Aug; 82(8):874-886. PubMed ID: 28941455
[TBL] [Abstract][Full Text] [Related]
17. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
18. Immunochemical crossreactivity of antibodies specific for "advanced glycation endproducts" with "advanced lipoxidation endproducts".
Richter T; Münch G; Lüth HJ; Arendt T; Kientsch-Engel R; Stahl P; Fengler D; Kuhla B
Neurobiol Aging; 2005 Apr; 26(4):465-74. PubMed ID: 15653175
[TBL] [Abstract][Full Text] [Related]
19. Effect of aldehydes derived from oxidative deamination and oxidative stress on beta-amyloid aggregation; pathological implications to Alzheimer's disease.
Chen K; Kazachkov M; Yu PH
J Neural Transm (Vienna); 2007; 114(6):835-9. PubMed ID: 17401529
[TBL] [Abstract][Full Text] [Related]
20. epsilon-Glycation, APP and Abeta in ageing and Alzheimer disease: a hypothesis.
Schmitt HP
Med Hypotheses; 2006; 66(5):898-906. PubMed ID: 16442744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
